Kesimpta, known generically as ofatumumab, is a medication used primarily to treat multiple sclerosis (MS), an autoimmune disease where the immune system mistakenly attacks the nervous system. Because Kesimpta works by targeting and reducing certain immune cells (specifically B-cells), it can influence the body’s ability to fight infections. This raises the important question: does Kesimpta cause infections?
Yes, Kesimpta can increase the risk of infections. This is because it suppresses parts of the immune system that normally help protect the body from bacteria, viruses, and other pathogens. When these immune cells are lowered, the body becomes more vulnerable to infections that it might otherwise control effectively.
In clinical studies and patient reports, infections have been observed as a relatively common side effect of Kesimpta. These infections are often mild to moderate and include upper respiratory tract infections such as colds and nasopharyngitis (inflammation of the nose and throat). Some patients also experience urinary tract infections and other types of infections, but serious infections are less common. The overall rate of infections in patients taking Kesimpta is similar to that seen with other MS treatments, indicating that while the risk is increased, it is not unusually high compared to alternative therapies.
Injection-related reactions are also common with Kesimpta, but these are different from infections. They typically involve redness, swelling, or pain at the injection site and are usually temporary.
Because Kesimpta reduces B-cells, which play a role in immune defense, patients are advised to be vigilant for signs of infection. Symptoms such as fever, chills, sore throat, muscle aches, or unusual fatigue should prompt immediate medical attention. Early detection and treatment of infections are important to prevent complications.
Doctors generally monitor patients closely during Kesimpta treatment to manage infection risks. This includes regular blood tests to check immune cell levels and overall health. Patients are also advised to avoid exposure to contagious illnesses when possible and to maintain good hygiene practices.
It is important to note that while Kesimpta increases infection risk, it does not cause infections directly. Instead, it creates a condition where the body’s natural defenses are lowered, making infections more likely if exposed to infectious agents.
In summary, Kesimpta does cause an increased risk of infections due to its immune-suppressing action, but these infections are usually manageable with proper medical care and monitoring. Patients on Kesimpta should be aware of infection symptoms and maintain close communication with their healthcare providers to ensure any infections are treated promptly.
